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Among 792 patients with multiple myeloma treated from 1987 to 2010 and assessed after 18 months, there were 167 patients with
complete remission. For those 60 patients treated between 1987–1998 and with long followup, the latest relapse occurred after 11.8
years,sothat13patientshaveremainedinsustainedcompleteremissionforlongerthan12years(range12–22years).Theseresults
suggest that 3% of all patients treated during that period may be cured of multiple myeloma. In addition to immunoﬁxation, more
sensitive techniques for the detection of residual disease should be applied more consistently in patients with apparent complete
remission in order to identify those with potential cure.
1.Introduction
In recent years, there have been major advances in the treat-
ment of multiple myeloma, due to new agents, superior drug
combinations, and widespread use of intensive therapy
supported by autologous stem cells [1–5]. Thus, remission
of disease has been achieved in 85–90% of currently treated
patients, including 30–40% with complete remission (CR)
[5–8]. This paper assessed the potential for curability among
792 patients with newly diagnosed myeloma treated at a
single center over a long time span.
2. Patientsand Methods
Between 1987–2010, we identiﬁed 792 newly diagnosed
patients treated with primary, intermittent, high-dose
dexamethasone-based regimens in sequential protocols (e.g.,
VAD, combinations with thalidomide, bortezomib, etc.) [1–
3, 7, 8]. Patients older than 65 were excluded in order to
assess results among those more likely to receive intensive
therapy. Patients with nonsecretory or “hyposecretory”
disease (e.g., only Bence Jones protein <50mg/day) were
excluded in order to deﬁne remission status clearly (Table 1).
In order to assess the impact of improved treatments and the
impact of prolonged complete remission (CR), we assessed
outcomes separately for those treated initially between 1987–
1998 or 1999–2010. None of the patients treated between
1987–1998hadreceivedthalidomide,lenalidomide,orborte-
zomib at diagnosis, but approximately 25% had received at
least one of these drugs upon relapse; in contrast, all of
the 330 patients treated between 1999–2010 had received
at least one of those drugs as part of primary or salvage
therapy. Cytogenetics was not evaluated since few patients
were studied during the early treatment period.
Among all patients, intensive therapy (HDT) supported
by autologous stem cells had been given within 1 year to
35% of those treated between 1987–1998 and to 82% of
those treated later (P<. 01). Details of these treatments have
beendescribed[9,10].Allpatientswhoreceivedthediﬀerent
primary therapies were combined in the analysis, as were
all patients who received the diﬀerent HDT. (Most patients
who had not received HDT had been denied insurance
coverage, especially prior to 2000). Written permission for
this retrospective review was provided by our Institutional
Review Board, in accordance with an assurance approved by
the Department of Health and Human Services.
3.ClinicalResponse and StatisticalMethods
Partial response (PR) was deﬁned as reduction of serum
myeloma protein by >50% and of Bence Jones protein by2 Bone Marrow Research
Table 1: Patient population (1987–2010).
No. patients 1070
Age > 65 −246
Non secretory or
hyposecretory
−32
No. studied 792
1987–1998 (%) 1999–2010 (%) P
No. patients 462 330
Deaths < 18 mo 96 (21) 35 (11) <.01
No. HDT < 12 mo 162 (35) 272 (82) <.01
Response status at 18 mo (%)
No. patients 366 295
NR 57 (16) 13 (5)
175 (59)
107 (36)
⎫
⎪ ⎪ ⎪ ⎬
⎪ ⎪ ⎪ ⎭
PR 249 (68) <.01
CR 60 (16)
Duration of CR N o .( %o fC R )
>3 years 43 (72) 60 (56)
>12 years 13 (22) n.a.
>90%. CR required disappearance of myeloma protein by
immunoﬁxation for at least 2 months [11]. Duration of CR
was calculated from onset of CR to earliest sign of relapse,
such as myeloma protein recurrence by immunoﬁxation,
new bone lesions, or marrow plasmacytosis.
Survival was calculated using the Kaplan and Meier
method and diﬀerences between groups compared using the
log-rank test [12, 13]. Since we desired to compare survival
for patients with diﬀerent degrees of response, landmark
analysiswasconductedafter18monthstoavoidthepotential
bias of guaranteed survival. For 12 patients with onsets of
PR or CR to later rescue treatments, survival and remission
were censored at such change in status [14]; survival and
remission were also censored at the last electrophoresis or
immunoﬁxation for 6 patients with CR or PR who died of
unrelated diseases. Thus, 131 patients who died within 18
months were excluded from the survival analysis, including
80 patients with NR, 48 patients with PR, and 3 patients with
CR;42 ofthe131 patients hadreceivedHDTwithtreatment-
related deaths in 13 patients.
4. Results
4.1. Remission and Survival. The best remission status at
18 months following primary treatment was deﬁned for all
661 patients alive at that time and subsequent survival by
landmark analysis was assessed for each group based on
response status. Among recently treated patients, there were
signiﬁcantly higher frequencies of CR (36 versus 16%) and
lower frequencies of NR (5 versus 16%), in comparison with
earlierpatients(Table 1).Figure 1notonlydepictsthelonger
survival for all patients treated since 1999 in comparison
with the earlier group, but also the similar survival for each
response status among those treated in the diﬀerent time
frames.
4.2.CompleteRemission. Wefocusedonlong-termoutcomes
forthe167patientswithCRat18monthsamongwhom86%
had received HDT, in comparison with 51% of those with
NR or PR (P<. 01). Figure 2 shows the duration of CR for
60 patients treated between 1987–1998 and for 107 patients
treated between 1999–2010, with longer duration among
those treated during the earlier period (a); after landmark
of 3 years following primary treatment, the diﬀerences were
not signiﬁcant (b). For the early treatment period, relapse
of myeloma has not been seen in any patient after 12 years
of CR, identifying 13 patients with sustained CR > 12 years
(3%ofallpatientsand22%ofthosewithCR).Clearplateaus
in survival (Figure 1(a)) and in duration of CR (Figure 2(a))
were evident in patients with CR > 12 years. Yet, the higher
frequency of CR with recent therapies was associated with a
shorter remission time. All 13 patients with prolonged CR
showed levels of uninvolved IgM that were either normal at
diagnosis (>40mg/dL) (9 patients) or had recovered to this
level within 1 year of CR (4 patients).
We assessed various clinical features that might dis-
tinguish the 13 patients with CR > 12 years from the
remaining 47 patients with shorter CR. There were no
apparent diﬀerences in age, stage of disease, the frequency
of HDT, or the pathway to reach CR with or without HDT.
In addition, there was no correlation of prolonged CR with
pretreatment levels of serum B2M, LDH, and uninvolved
IgA.
5. Discussion
In the past, criteria for improved treatments for multiple
myeloma had focused on the achievement of higher response
rates and longer survival. With the wider application of
new drugs and intensive therapies, progressively higher
frequencies of CR have been observed in recent years [6–
8, 15–17]. Among all patients treated, frequencies of CR
have increased from approximately 5% prior to 1987, to
approximately 15% for those treated between 1987–1998,
and to approximately 30% for those treated in recent year
[4–8,15–18].Ourpaperfocusedonlong-termoutcomesand
the potential for cure among patients with prolonged CR.
Criteria for complete remission, based on negative
immunoﬁxation sustained for at least 2 months, have been
accepted for several years [11]. Greater sensitivities for the
deﬁnition of CR have also been proposed using criteria that
include the disappearance of clonal plasma cells by negative
phenotype, normal molecular studies, and normal PET-
scanning studies [19–21]. Further studies in large numbers
of patients followed for long periods are required to clarify
the added value of these procedures.
There has been recent controversy concerning the
prospectofcureforpatientswithmultiplemyeloma[22–24].
The diﬀerences expressed have focused on the deﬁnition of
CR and the uncertainty concerning the duration of CR. In
regard to the deﬁnition of CR, many centers have considered
patients with “near” CR as equivalent to CR, while others
have included some patients with PR after reasoning that the
residual monoclonal component may represent an MGUSBone Marrow Research 3
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Figure 1: Survival after landmark of 18 months for all patients (a) and for those with NR, PR, or CR as best response at 18 months, with
patients separated by early versus later treatment period. Note: longer survival among all patients treated recently but similar survival for
patients with the same response status.
status that preceded multiple myeloma [6, 22–24]. Even
though many patients with “near” CR or PR have long
survival, there is no evidence of a plateau in survival times
for such patients, such as we describe here and others
have described previously for patients with CR deﬁned by
negativeimmunoﬁxation[25].DeﬁnitionsofCRthatarenot
rigorous inﬂate the true frequency of CR and handicap the
identiﬁcation of those with meaningful potential for cure.
Furthermore, Lahuerta et al. and Martinez-Lopez et al. have
described signiﬁcant diﬀerences in survival among patients
with CR, near CR, or very good PR [5, 25]. Barlogie et al.
havealsoshownthattheimplicationsofCRmaybeoverrated
since the duration of CR may be short (i.e., <3y e a r s )d u et o
early relapse of a more proliferative clone [18].
Following the sequence of conventional primary therapy
followed by HDT supported by autologous stem cells, we
observed a clear plateau in duration of CR and in survival
for patients with CR sustained for at least 12 years. These
ﬁndings aﬃrm those described recently by Martinez-Lopez
et al. who observed that patients treated from 1989–1998
and with sustained CR for longer than 11 years may be
cured [25]. In our study, the higher frequency of CR
with recent therapies was associated with shorter remission
time, but this diﬀerence was not evident after requiring a
landmark survival of 3 years. The validity of these ﬁndings
are uncertain since the 2 groups of patients with CR were
not comparable in terms of their primary therapies, the
frequencies of HDT, and the unknown cytogenetic proﬁles.4 Bone Marrow Research
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Figure 2: Durations of complete remission for 60 patients treated from 1987 to 1998 and for 107 patients treated from 1999 to 2010 (a).
Durations of complete remission for the same group of patients after landmark of 3 years following primary therapy (b).
Also, Barlogie et al. have associated high frequencies of
CR after intensive therapy with short durations in many
patients, such as observed among many of our patients
treated recently [18]. However, despite the more frequent
use of HDT and new agents in the more recent cohort, the
durations of CR appeared to be shorter so that CR as now
deﬁned may not be as predictive of cure as had appeared
previously.
In view of the long CR in many patients and the potential
for cure in some, maintenance therapy for CR remains
controversialunlessprognosticfactorsidentifythosewhoare
more likely to have short CR. Until such guidelines become
available, prolonged maintenance therapy may increase the
likelihood of side eﬀects, increase the cost, and promote
resistance to later drug combinations upon relapse.
6. Conclusion
In this retrospective review of a large number of patients
withmultiplemyeloma,wehavenotobserveddiseaserelapse
in any patient with CR sustained for at least 12 years. For
13 such patients, who represented 3% of those treated from
1987 to 1998, there were clear plateaus in the duration of CR
and in survival that were consistent with apparent cure of
multiple myeloma.
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